# The Study on Effects of CYP3A and P-glycoprotein Inhibitor Itraconazole and CYP Enzyme Inducer Rifampin of HMPL-453 Tartrate Tablets

> **NCT07697157** · PHASE1 · COMPLETED · sponsor: **Hutchmed** · enrollment: 40 (actual)

## Conditions studied

- Health, Subjective

## Interventions

- **DRUG:** HMPL-453 with Itraconazole
- **DRUG:** HMPL-453 with Rifampin

## Key facts

- **NCT ID:** NCT07697157
- **Lead sponsor:** Hutchmed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-03-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2026-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07697157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07697157, "The Study on Effects of CYP3A and P-glycoprotein Inhibitor Itraconazole and CYP Enzyme Inducer Rifampin of HMPL-453 Tartrate Tablets". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07697157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*